Preparing for three critical payer questions to build an evidence-based market access and pricing strategy
A drug’s value (benefit/cost) is undergoing unprecedented examination. Pharmaceutical companies are faced not only with the challenges of payers, but also with the rigorous drug evaluation standards of Health Technology Assessment (HTA) groups. Navigating the healthcare landscape to ensure adoption of your drug demands robust strategies and tactics to support its development to ultimately achieve commercial success.
Join our complimentary webinar to hear Ipsos’ experts in HEOR and market access strategy explore the three most critical payer & HTA questions that pharmaceutical companies must be prepared to address:
- Can the drug work?
- Does the drug work?
- Is the drug worth it?
Some key takeaways
You will hear insights and recommendations spanning:
- Generation and communication of payer-relevant disease and drug evidence
- Key considerations for developing an effective payer value proposition
- Design of compelling, evidence-based market access and pricing strategies and tactics
Armed with this intelligence, you will have a better understanding of how to address the three critical payer & HTA questions, and thus be able to develop the necessary strategies and tactics to achieve commercial success.
If you are attending ISPOR 2019 in New Orleans USA (May 18-22), we would be delighted to meet up with you onsite! Come visit our team at booth #409 – visit our 14 posters for evidence, value and access insights – or reach out to email@example.com to join our client dinner.
Tom Hughes, BSPharm, PhD, Senior Vice President, HEOR, US, Healthcare
Colin Nash, Vice President, Market Access, US, Healthcare